Pulmonary Fibrosis Biomarkers Market, By Type of Biomarkers, By Application, By End-user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

Description

REPORT HIGHLIGHT

Pulmonary Fibrosis Biomarkers Market size was valued at US$ 4,290.43 Million in 2024, expanding at a CAGR of 4.50% from 2025 to 2032.

Pulmonary fibrosis biomarkers are biological indicators that help in the diagnosis, monitoring, and prognosis of pulmonary fibrosis, a progressive lung disease characterized by scarring of lung tissue. These biomarkers can be proteins, genes, or other molecules present in blood, urine, or tissue samples. They assist in understanding the disease's progression and response to treatment. Biomarkers such as KL-6, SP-D, and CCL18 are often used to monitor disease activity and predict outcomes. Research into pulmonary fibrosis biomarkers is crucial for early detection, personalized treatments, and the development of new therapies. These biomarkers also help differentiate pulmonary fibrosis from other lung diseases with similar symptoms. As the disease can be difficult to diagnose, biomarkers provide valuable insights for clinicians to make more accurate decisions. With ongoing studies, these biomarkers are increasingly seen as essential tools for better patient management.

Pulmonary Fibrosis Biomarkers Market- Market Dynamics

Rising incidence of pulmonary fibrosis drives demand for biomarkers in diagnosis.

The increasing incidence of pulmonary fibrosis (PF) is a key driver for the growth of the biomarkers market. In countries like India, the prevalence of idiopathic pulmonary fibrosis (IPF) is rising, with estimates ranging between 14 to 43 per 100,000 people. This growing number of cases highlights the urgent need for early and accurate diagnosis. A study revealed that IPF accounts for approximately 17% of all interstitial lung diseases (ILDs) in the country, emphasizing the importance of detecting the condition early to manage it effectively. Furthermore, regions like Pune have seen a 5-7% annual increase in IPF cases, which further underscores the demand for advanced diagnostic tools. As pulmonary fibrosis cases continue to rise globally, the need for reliable biomarkers that can diagnose, monitor disease progression, and assess treatment efficacy is more critical than ever, driving the demand for innovation in this market.

Pulmonary Fibrosis Biomarkers Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.50% over the forecast period (2025-2032)

Based on Type of Biomarkers segmentation, Diagnostic Biomarkers was predicted to show maximum market share in the year 2024

Based on application segmentation, Diagnosis was the leading application in 2024

Based on End-user segmentation, Diagnosis laboratories was the leading End-user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Pulmonary Fibrosis Biomarkers Market- Segmentation Analysis:

The Global Pulmonary Fibrosis Biomarkers Market is segmented on the basis of Type of Biomarkers, Application, End-user, and Region.

The market is divided into three categories based on Type of Biomarkers: Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers. The Diagnostic Biomarkers segment is the most prominent and significant in the Pulmonary Fibrosis Biomarkers market. Early and accurate diagnosis of pulmonary fibrosis (PF) is crucial for improving patient outcomes, and diagnostic biomarkers play a vital role in this process. These biomarkers are essential in identifying the presence of PF at its early stages, when intervention can still slow disease progression. With diseases like idiopathic pulmonary fibrosis (IPF) being challenging to diagnose due to their similarities with other lung conditions, diagnostic biomarkers help differentiate PF from other diseases, leading to quicker and more accurate diagnoses. Biomarkers such as KL-6, SP-D, and CCL18 are increasingly being used in clinical settings to aid in diagnosing IPF and other forms of pulmonary fibrosis. The growing awareness of PF and its high incidence rate in regions like the U.S. further intensifies the need for reliable diagnostic tools. This demand is driving the research and development of new, more efficient biomarkers, ensuring that the diagnostic biomarkers segment remains dominant in the market.

The market is divided into three categories based on application: Diagnosis, Treatment Monitoring, Drug Development. The diagnosis segment is the most significant in the Pulmonary Fibrosis Biomarkers market. Early and accurate diagnosis of pulmonary fibrosis (PF) is crucial for improving patient outcomes and enabling timely treatments. Since PF, particularly idiopathic pulmonary fibrosis (IPF), shares symptoms with other lung diseases, it is often misdiagnosed, making diagnostic biomarkers vital for distinguishing it from similar conditions. Biomarkers such as KL-6, SP-D, and CCL18 are commonly used in clinical practice for their ability to detect PF at early stages, when interventions are most effective in slowing disease progression. With the rising prevalence of PF, there is an increasing demand for precise diagnostic tools, driving the focus on developing new biomarkers for early detection. Moreover, as research institutions and healthcare providers emphasize early diagnosis, the diagnostic application remains central to the growth and innovation in the pulmonary fibrosis biomarkers market.

Pulmonary Fibrosis Biomarkers Market- Geographical Insights

North America is a leading region in the Pulmonary Fibrosis Biomarkers market due to its advanced healthcare infrastructure, high prevalence of pulmonary diseases, and ongoing research initiatives. The United States, in particular, has a significant share in the market, supported by the presence of top-tier research institutions, pharmaceutical companies, and a growing number of clinical trials. With approximately 200,000 individuals diagnosed with idiopathic pulmonary fibrosis (IPF) in the U.S., there is a strong demand for diagnostic biomarkers to aid early detection and management. Furthermore, government programs, like the National Institutes of Health (NIH), are funding research to identify and validate biomarkers, boosting innovation. The region's strong healthcare reimbursement systems also ensure that emerging biomarkers are adopted into clinical practice. Additionally, rising awareness about the disease and advancements in personalized medicine are further propelling market growth.

The United States plays a dominant role in the Pulmonary Fibrosis Biomarkers market due to its advanced healthcare system and substantial investment in medical research. With over 200,000 individuals diagnosed with idiopathic pulmonary fibrosis (IPF), the demand for effective biomarkers for early detection, prognosis, and treatment monitoring is growing rapidly.

The U.S. government, through agencies like the National Institutes of Health (NIH), is heavily funding research to discover new biomarkers. This, in turn, accelerates the development of diagnostic tools and therapies for IPF. The country also boasts a robust pharmaceutical industry that actively collaborates with research institutions to advance biomarker-driven solutions

Pulmonary Fibrosis Biomarkers Market- Competitive Landscape:

The competitive landscape of the Pulmonary Fibrosis Biomarkers market is marked by the presence of both established pharmaceutical giants and specialized biotech companies. Major players like Genentech, F. Hoffmann-La Roche, and Gilead Sciences dominate the market due to their extensive research capabilities and robust portfolios in pulmonary diseases.

These companies focus on advancing biomarker discovery, conducting clinical trials, and integrating biomarkers into treatment protocols. At the same time, smaller biotech firms like Biodesix and Thermo Fisher Scientific are making significant strides with innovative biomarker platforms and diagnostic tools tailored for pulmonary fibrosis. The competitive environment is also driven by strategic collaborations between pharmaceutical companies and research institutions, aimed at accelerating biomarker validation and commercialization. As the market evolves, companies are increasingly adopting personalized medicine approaches, further intensifying competition.

Recent Developments:

In October 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for BMS-986278, a first-in-class oral lysophosphatidic acid receptor 1 (LPA1) antagonist, for the treatment of progressive pulmonary fibrosis (PPF), a severe and life-threatening disease. This designation expanded the company's product portfolio.

In March 2020, Bristol Myers Squibb entered into a collaboration with the Pulmonary Fibrosis Foundation (PFF) to identify biomarkers. The partnership aimed to accelerate the development of targeted therapies for this challenging condition, reflecting the company's commitment to enhancing patient outcomes. This initiative helped boost sales and revenue.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Biodesix, Inc.
Genentech, Inc.
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
AbbVie Inc.
Thermo Fisher Scientific Inc.
Abbott Laboratories
PerkinElmer, Inc.
Eli Lilly and Company
Gilead Sciences, Inc.
Novartis International AG
Johnson & Johnson
Mylan N.V.
Sanofi S.A.
Amgen Inc.

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY TYPE OF BIOMARKERS- MARKET ANALYSIS, 2019 - 2032

Diagnostic Biomarkers
Prognostic Biomarkers
Predictive Biomarkers

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

Diagnosis
Treatment Monitoring
Drug Development

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals & Clinics
Diagnostic Laboratories
Research & Academic Institutions

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV4936

1. Pulmonary Fibrosis Biomarkers Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Pulmonary Fibrosis Biomarkers Market Snippet by Type of Biomarkers
- 2.1.2. Pulmonary Fibrosis Biomarkers Market Snippet by Application
- 2.1.3. Pulmonary Fibrosis Biomarkers Market Snippet by End-user
- 2.1.4. Pulmonary Fibrosis Biomarkers Market Snippet by Country
- 2.1.5. Pulmonary Fibrosis Biomarkers Market Snippet by Region
2.2. Competitive Insights

3. Pulmonary Fibrosis Biomarkers Key Market Trends

3.1. Pulmonary Fibrosis Biomarkers Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Pulmonary Fibrosis Biomarkers Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Pulmonary Fibrosis Biomarkers Market Opportunities
3.4. Pulmonary Fibrosis Biomarkers Market Future Trends

4. Pulmonary Fibrosis Biomarkers Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Pulmonary Fibrosis Biomarkers Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Pulmonary Fibrosis Biomarkers Market Landscape

6.1. Pulmonary Fibrosis Biomarkers Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Pulmonary Fibrosis Biomarkers Market - By Type of Biomarkers

7.1. Overview
- 7.1.1. Segment Share Analysis, By Type of Biomarkers, 2024 & 2032 (%)
- 7.1.2. Diagnostic Biomarkers
- 7.1.3. Prognostic Biomarkers
- 7.1.4. Predictive Biomarkers

8. Pulmonary Fibrosis Biomarkers Market - By Application

8.1. Overview
- 8.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
- 8.1.2. Diagnosis
- 8.1.3. Treatment Monitoring
- 8.1.4. Drug Development

9. Pulmonary Fibrosis Biomarkers Market - By End-user

9.1. Overview
- 9.1.1. Segment Share Analysis, By End-user, 2024 & 2032 (%)
- 9.1.2. Hospitals & Clinics
- 9.1.3. Diagnostic Laboratories
- 9.1.4. Research & Academic Institutions

10. Pulmonary Fibrosis Biomarkers Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.8. UK
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. UK Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.3.8.4. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.8.5. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.9. France
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. France Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.3.9.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.9.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.10. Italy
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. Italy Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.3.10.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.10.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.11. Spain
  - 10.3.11.1. Overview
  - 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.3. Spain Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.11.5. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.12. The Netherlands
  - 10.3.12.1. Overview
  - 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.3. The Netherlands Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.3.12.4. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.12.5. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Overview
  - 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.13.5. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.14. Russia
  - 10.3.14.1. Overview
  - 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.3. Russia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.14.5. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.15. Poland
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Poland Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.16. Rest of Europe
  - 10.3.16.1. Overview
  - 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.3.16.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.7. China
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. China Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.4.7.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.7.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.8. India
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. India Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.4.8.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.8.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.12. Indonesia
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Indonesia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.13. Thailand
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Thailand Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.8. UAE
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. UAE Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.6.8.4. UAE Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.6.8.5. UAE Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Pulmonary Fibrosis Biomarkers Industry

11.1. Competitive Dashboard
- 11.1.1. Competitive Benchmarking
- 11.1.2. Competitive Positioning
11.2. Company Profiles
- 11.2.1. Biodesix, Inc.
- 11.2.2. Genentech, Inc.
- 11.2.3. F. Hoffmann-La Roche Ltd.
- 11.2.4. Bristol-Myers Squibb Company
- 11.2.5. AbbVie Inc.
- 11.2.6. Thermo Fisher Scientific Inc.
- 11.2.7. Abbott Laboratories
- 11.2.8. PerkinElmer, Inc.
- 11.2.9. Eli Lilly and Company
- 11.2.10. Gilead Sciences, Inc.
- 11.2.11. Novartis International AG
- 11.2.12. Johnson & Johnson
- 11.2.13. Mylan N.V.
- 11.2.14. Sanofi S.A.
- 11.2.15. Amgen Inc.

12. 360 Degree AnalystView

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us